



PATENT NO. PI 2023000737




## Metastatic Cancer



## Our Solution



## How It Works?



### BRIEF TECHNOLOGY

- Our compound, **SRS28** is a **DDAG derivative** where an acetyl group is added to the **natural compound, 14-deoxy-11-dehydroandrographolide**.

### CURRENT ISSUES


- **Metastatic cancer is deadly.**
- **>90% of cancer related deaths** are due to metastasis → **poor five-year survival rate.**
- **Treatment of metastasis is challenging** due to the advance pathways.
- **Current treatments are ineffective** as tumors evolve
- **Patients are not able to afford** the current **expensive treatment options.**

### INVENTIVENESS & NOVELTY

- First DDAG analogue to have anti metastatic effect without killing the cancer cells.

### USEFULNESS & APPLICATION

- SRS28 can be administered through various routes to patients suffering from metastatic cancer.



### IMPACT OF THE PRODUCT

- SRS28 is an alternative solution to current treatment options which are expensive and often ineffective.
- Can target metastatic cancers as the compound can inhibit vital process of metastasis

### MARKET POTENTIAL

- Pharmaceutical industries

### Technology Readiness Level (TRL)

4 –Lab Validation

### THE TEAM



Dr. Jonathan Lim Chee Woei  
PRINCIPAL INVESTIGATOR



Dr. Sreenivasa Rao Sagineedu  
SYNTHESIS OF THE COMPOUND



Anoocha Saud  
CARRIED OUT *IN VITRO* AND *IN VIVO* TESTING OF THE COMPOUND



Dr. Wong Mei Szin  
CARRIED OUT *IN VITRO* AND *IN VIVO* TESTING OF THE COMPOUND



Project Leader : Prof. Johnson Stanslas  
Dept./Faculty : Medicine/ Faculty of Medicine and Health Sciences  
Email : rcxjs@upm.edu.my  
Phone : 603-97692310  
Expertise : Pharmacology & Toxicology

#UNSDG



www.sciencepark.upm.edu.my